Abstract
The availability of antemortem biomarkers for Alzheimer's disease (AD) enables monitoring the evolution of neurodegenerative processes in real time. Pittsburgh compound B (PIB) positron emission tomography (PET) was used to select participants in the Mayo Clinic Study of Aging and the Mayo Alzheimer's Disease Research Center with elevated β-amyloid, designated as “A+,” and hippocampal volume and 18fluorodeoxyglucose (FDG) positron emission tomography were used to characterize participants as having evidence of neurodegeneration (“N+”) at the baseline evaluation. There were 145 clinically normal (CN) A+ individuals, 62 persons with mild cognitive impairment (MCI) who were A+ and 20 with A+ AD dementia. Over a period of 1–6 years, MCI A+N+ individuals showed declines in medial temporal, lateral temporal, lateral parietal, and to a lesser extent, medial parietal regions for both FDG standardized uptake value ratio and gray matter volume that exceeded declines seen in the CN A+N+ group. The AD dementia group showed declines in the same regions on FDG standardized uptake value ratio and gray matter volume with rates that exceeded that in MCI A+N+. Expansion of regional involvement and faster rate of neurodegeneration characterizes progression in the AD pathway.
Original language | English (US) |
---|---|
Pages (from-to) | 32-42 |
Number of pages | 11 |
Journal | Neurobiology of Aging |
Volume | 46 |
DOIs | |
State | Published - Oct 1 2016 |
Externally published | Yes |
Keywords
- Alzheimer's disease
- FDG PET imaging
- Longitudinal study
- MR imaging
- PIB PET imaging
ASJC Scopus subject areas
- Clinical Neurology
- General Neuroscience
- Aging
- Developmental Biology
- Geriatrics and Gerontology